


Amendments to the Claims

This claim listing will replace all prior versions of claims and claim listings in the application:

1. (Currently amended) A compound structurally represented by Formula I,



or pharmaceutically acceptable salts thereof, wherein:

R¹ and R² are independently H, or -O R³ N R⁴ R⁵, provided that one of R¹ and R² is -O R³ N R⁴ R⁵, and provided that only one of R¹ and R² is ~~can be~~ -O R³ N R⁴ R⁵;

R³ is ~~(C₂-C₅)~~ (C₂-C₅) alkylene;

R⁴ is (C₁-C₄) alkyl;

R⁵ is (C₁-C₄) alkyl,

wherein R⁴ and R⁵ taken together with the nitrogen atom to which they are attached can form a piperidinyl or pyrrolidinyl ring;

X is CH₂ or CO;

Y and Z are ~~-CH₂-~~ -CH₂- or N, provided that one of Y or Z is N, and provided that only one of Y and Z ~~can be~~ is N;

R⁶ is hydrogen,

- (C₁-C₄) alkyl,

-CH₂ -phenyl,

-CH₂ (C₃-C₇) cycloalkyl,

-CO₂R⁸,

-SO₂R⁹,

-CONH R¹⁰,

-COR¹¹,

-CH₂CH₂N R¹² R¹³, or

-CH₂R¹⁴;

R⁷ is hydrogen,

-(C₁-C₄) alkyl,

-CH₂ - phenyl,

-CH₂(C₃-C₇) cycloalkyl,

-CO₂R⁸,

-SO₂R⁹,

-CONH R¹⁰,

-COR¹¹,

-CH₂CH₂N R¹² R¹³, or

-CH₂R¹⁴;

Wherein;

R⁸ is

-(C₁-C₄) alkyl, or

-(C₃-C₇) cycloalkyl;

R⁹ is

-(C₁-C₄) alkyl,

-(C₃-C₇) cycloalkyl, or

- phenyl;

R¹⁰ is

-(C₁-C₄) alkyl, or

-(C₃-C₇) cycloalkyl;

R¹¹ is

-(C₁-C₄) alkyl,

-(C₃-C₇) cycloalkyl,

-CH₂N R¹² R¹³, or

-(C₃-C₇) cycloalkyl, wherein optionally one or more of said carbons is replaced by N, NR¹⁰, or NCO₂ R¹⁰;

R¹² is

- hydrogen, or
- (C₁-C₄) alkyl;






R¹³ is







- hydrogen,
- (C₁-C₄) alkyl,
- CO₂R¹⁰, or
- phenyl;









R¹⁴ is








- (C₁-C₄) alkyl, or
- (C₃-C₇) cycloalkyl, wherein optionally one or more of said carbons is replaced by N, NR¹⁰, or NCO₂R¹⁰.









2. (Original) The compound of claim 1, wherein R² is hydrogen and R¹ is -O R³ N R⁴ R⁵.
3. (Original) The compound of claim 2 wherein R³ is -CH₂CH₂CH₂-.
4. (Currently amended) The compound of ~~any of claims 1-3~~ claim 3 wherein R⁴ and R⁵ taken together with the nitrogen atom to which they are attached form a piperidinyl ring.
5. (Currently amended) The compound of ~~any of claims 1-4~~ claim 1 wherein Z is N and Y is CH₂.
6. (Currently amended) The compound of ~~any of claims 1-4~~ claim 1 wherein Y is N and Z is CH₂.
7. (Currently amended) The compound of ~~any of claims 1-6~~ claim 1 wherein X is CO.
8. (Currently amended) The compound of claim 1 further represented by any one of formula (Example 1) to (Example 36) selected from the group consisting of:



Example Number	Structure
1	 <chem>CC(C)(C)OC(=O)N1CCc2ccc(OCCCN3CCCCC3)cc21</chem>
2	 <chem>C1CCc2ccc(OCCCN3CCCCC3)cc21</chem> CH CH
3	 <chem>CC(C)N(C(=O)N1CCc2ccc(OCCCN3CCCCC3)cc21)C</chem>
4	 <chem>c1ccccc1CN1CCc2ccc(OCCCN3CCCCC3)cc21</chem>
5	 <chem>C1CCCCC1CN1CCc2ccc(OCCCN3CCCCC3)cc21</chem>

6	 <chem>CC(C)N1CCc2ccc(OCCCN3CCCCC3)cc21</chem>
7	 <chem>CC1(CCC1)CN2CCc3ccc(OCCCN4CCCCC4)cc32</chem> <chem>CC(=O)C(=O)O</chem>
8	 <chem>CN(C)CC(=O)N1CCc2ccc(OCCCN3CCCCC3)cc21</chem>
9	 <chem>CCN1CCc2ccc(OCCCN3CCCCC3)cc21</chem>
10	 <chem>c1ccccc1CN2CCc3ccc(OCCCN4CCCCC4)cc32</chem>
11	 <chem>CC1(CCC1)CN2CCc3ccc(OCCCN4CCCCC4)cc32</chem>

12	
13	
14	
15	
16	
17	
18	
19	

20	
21	 CH CH
22	 CH CH
23	
24	
25	 Chiral
26	

27	
28	 Chiral
29	
30	 HCl HCl
31	
32	 Chiral
33	 CH CH
34	

35	
36	

- or a pharmaceutically acceptable salt or solvate thereof.
9. (Currently amended) A pharmaceutical composition which comprises a compound of ~~any of claims 1-8~~ 1 or 8 and a pharmaceutically acceptable carrier.
 10. (Cancelled)
 11. (Cancelled)
 12. (Cancelled)
 13. (Currently amended) A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of Claims 1-8~~ 1 or 8.
 14. (Original) The method of Claim 13 wherein the antagonist is a pharmaceutical composition of claim 9.
 15. (Currently amended) A method for treatment or prevention of a cognitive disorder ~~or disease in which inhibition of the histamine H3 receptor has a beneficial effect~~ which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of claims 1-8~~ 1 or 8.
 16. (New) The method of Claim 15 wherein the antagonist is a pharmaceutical composition of claim 9.